Abstract
Our objective was to clarify the clinical and biological characteristics of basal-like breast cancer (BLBC) and non-basal-like breast cancer (TN3BKE) in Heilongjiang. We examined, by immunohistochemistry, expression of biological markers cytokeratin (CK) 5/6 and epidermal growth factor receptor (EGFR) and B cell specific moloney murine leukemia virus integration site 1( Bmi-1) in triple-negative breast cancer (TNBC). We studied the correlation between BLBC and several factors related to tumor progression, along with its prognostic value. In the 229 cases of operable TNBC, BLBC was detected in 178 (77.7%) and TN3BKE- in 51 (22.2%). There was no significant difference in clinicopathological factors between them, However, BLBC was significantly associated with Bmi-1 expression (P=0.000) and shorter disease-free survival (DFS) (P = 0.045) and overall survival (OS) (P=0.041). Compared with the non-basal group, patients with BLBC have a high expression of Bmi-1 and a poor prognosis.
Highlights
Breast cancer comprises an extraordinarily diverse group of diseases in terms of presentation, morphology, molecular profile, and response to therapy, Gene expression analysis has identified molecular classes of breast cancer that are biologically and clinically distinct, and by that breast cancer was classified into five subtypes: luminal A, luminal B, HER2-overexpressing, normalbreast-like, and basal-like breast cancer (BLBC)
We studied the correlation between BLBC and several factors related to tumor progression, along with its prognostic value
There was no significant difference in clinicopathological factors between them, BLBC was significantly associated with Bmi-1 expression (P=0.000) and shorter disease-free survival (DFS) (P = 0.045) and overall survival (OS) (P = 0.041)
Summary
Breast cancer comprises an extraordinarily diverse group of diseases in terms of presentation, morphology, molecular profile, and response to therapy, Gene expression analysis has identified molecular classes of breast cancer that are biologically and clinically distinct, and by that breast cancer was classified into five subtypes: luminal A, luminal B, HER2-overexpressing, normalbreast-like, and BLBC. The BLBC was defined as lacking both ER and HER2 expression, but it was positive for the expression of CK5/6 and EGFR The panel using these four antibodies showed a specificity of 100% and a sensitivity of 76% for the identification of BLBC (Nielsen et al, 2004). Methods: We examined, by immunohistochemistry, expression of biological markers cytokeratin (CK) 5/6 and epidermal growth factor receptor (EGFR) and B cell specific moloney murine leukemia virus integration site 1( Bmi-1) in triple-negative breast cancer (TNBC). Conclusions: Compared with the non-basal group, patients with BLBC have a high expression of Bmi-1 and a poor prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
